{"id":5521,"date":"2022-09-01T10:30:00","date_gmt":"2022-09-01T08:30:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/vd-koper-aktier-i-stayble-therapeutics\/"},"modified":"2022-09-01T10:30:00","modified_gmt":"2022-09-01T08:30:00","slug":"vd-koper-aktier-i-stayble-therapeutics","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/vd-koper-aktier-i-stayble-therapeutics\/","title":{"rendered":"VD k\u00f6per aktier i Stayble Therapeutics"},"content":{"rendered":"<p style=\"margin-bottom:0pt;margin-top:12px\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Andreas Gerward k&ouml;pte aktier den 31 augusti 2022 och f&ouml;rv&auml;rvade totalt 15<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">000 aktier till en kurs p&aring; 4,89 kronor per aktie, <\/span><span style=\"background-color:#ffffff;color:#3f3f3f;font-family:arial,helvetica,sans-serif;font-size:9pt\">och han &auml;ger d&auml;refter totalt 360<\/span><span style=\"background-color:#ffffff;color:#3f3f3f;font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"background-color:#ffffff;color:#3f3f3f;font-family:arial,helvetica,sans-serif;font-size:9pt\">000 aktier i Bolaget.<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"> <\/span><\/p>\n<p style=\"font-family:arial,helvetica,sans-serif;margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>Stayble Therapeutics AB (\u201dStayble\u201d eller \u201dBolaget\u201d) meddelar idag att Bolagets VD Andreas Gerward har k\u00f6pt 15\u00a0000 aktier i Bolaget till ett total v\u00e4rde om 73\u00a0350 SEK. Aktierna har k\u00f6pts i den l\u00f6pande handeln.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5521"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5521"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5521\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}